We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




New Method of Preparing Cells for Standard Cloning

By Biotechdaily staff writers
Posted on 24 Mar 2004
A new way to prepare custom competent cells at efficiencies suitable for standard cloning purposes has been developed.

The method entails the use of the RapidTransit Transformation Kit, which provides an economical and streamlined way to prepare chemically competent Escherichia coli cells at efficiencies suitable for standard cloning. More...
RapidTransit reagents eliminate complex buffer preparation and lengthy incubation periods while reducing the number of procedural steps. The kit has been used successfully to prepare competent cells from a wide variety of standard and specialized E coli strains, including popular K12 cloning strains and B strains (the BL21 family) used for recombinant protein expression.

The RapidTransit Transformation Kit offers two simple procedures to prepare competent cells: the direct addition method and the single-centrifugation method. The direct addition method allows for preparation of competent cells, transformation, and recovery within a single tube or well. The direct addition method provides transformation efficiencies of > 1 X 105 colony forming units (cfu)/µg supercoiled pUC18 plasmid DNA, whereas the single-centrifugation method provides reproducible transformation efficiencies of > 1 X 106 cfu/µg supercoiled pUC18 plasmid DNA, when using strain JM109.

"The RapidTransit system is an example of Sigma's commitment to the development of innovative products for cloning and recombinant protein expression,” said Keith Joliff, manager of global strategic marketing, molecular biology, at Sigma-Aldrich Corporation (St. Louis, MO, USA; www.sigmaaldrich.com), which developed the new system. "RapidTransit complements our current line of chemically competent and electrocompetent cells while providing researchers who require specialized strains or economical formats with a convenient alternative.”




Related Links:
Sigma-Aldrich Corp.

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
D-Dimer Test
Epithod 616 D-Dimer Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.